Perifosine treatment of prostate cancer cells results in subcellular mislocalization of AKT, which prevents AKT phosphorylation and subsequent phosphorylation of downstream substrates, all of which leads to cell growth arrest [120]. The gene discussed is AKT1; the disease is prostate cancer.